01 April 2026
01 April 2026
Lumitrace is currently approved in China and the US, with submission to EU regulatory authorities pending.
The programme enrolled 196 children, adolescents, and adults with either paediatric-onset or adult-onset HPP.
Symeres will assess Ambagon’s molecular glues through in vitro assays and mechanistic studies.
The integration supports treatment decisions across cancer care stages and helps reduce administrative tasks for clinicians.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
